• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Heart Transplantation - Pipeline Review, H2 2012 Product Image

Heart Transplantation - Pipeline Review, H2 2012

  • ID: 2335159
  • November 2012
  • 34 pages
  • Global Markets Direct

Heart Transplantation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Heart Transplantation - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Heart Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Transplantation. Heart Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Heart Transplantation.
- A review of the Heart Transplantation products under development by companies READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Heart Transplantation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Heart Transplantation 7
Heart Transplantation Therapeutics under Development by Companies 9
Heart Transplantation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Heart Transplantation Therapeutics – Products under Development by Companies 13
Heart Transplantation Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Heart Transplantation Therapeutics Development 15
Alexion Pharmaceuticals, Inc. 15
Portola Pharmaceuticals, Inc. 16
NasVax Ltd. 17
Heart Transplantation – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
TT-32 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Thymoglobulin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Anti-aCD3 Mab - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
JAK3 Program - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Heart Transplantation Therapeutics – Drug Profile Updates 28
Heart Transplantation Therapeutics - Dormant Products 30
Heart Transplantation – Product Development Milestones 31
Featured News & Press Releases 31
May 16, 2011: Chugai Pharma Files Application Seeking Japanese Approval For Pediatric Dosage And Administration Of CellCept 31
May 04, 2011: Argos Therapeutics´ Immunotherapy Platform Based On Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation 31
Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products Under Development for Heart Transplantation, H2 2012 7
Products under Development for Heart Transplantation – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Alexion Pharmaceuticals, Inc., H2 2012 15
Portola Pharmaceuticals, Inc., H2 2012 16
NasVax Ltd., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Heart Transplantation Therapeutics – Drug Profile Updates 28
Heart Transplantation Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Heart Transplantation, H2 2012 7
Products under Development for Heart Transplantation – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos